A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.

导出 OA

翻译打印收藏纠错

作者： Apostolos,Sarivalasis ^[1] ; Caroline,Boudousquié ^[1] ; Klara,Balint ^[1] ; Brian J,Stevenson ^[2] ; Philippe O,Gannon ^[3] ; Emanuela Marina,Iancu ^[1] ; Laetitia,Rossier ^[1] ; Silvia,Martin Lluesma ^[1] ; Patrice,Mathevet ^[2] ; Christine,Sempoux ^[1] ; George,Coukos ^[2] ; Urania,Dafni ^[4] ; Alexandre,Harari ^[5] ; Michal,Bassani-Sternberg ^[1] ; Lana E,Kandalaft ^[2]

作者单位： Department of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. ^[1] Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. ^[2] Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland. ^[3] Women-Mother-Child Department, Service of Gynecology, University Hospital of Lausanne, Lausanne, Switzerland. ^[4] Department of Pathology, University Hospital of Lausanne, Lausanne, Switzerland. ^[5] Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian, University of Athens, Athens, Greece. ^[6] Department of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. Lana.Kandalaft@chuv.ch. ^[7] Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. Lana.Kandalaft@chuv.ch. ^[8]

关键词 Cancer immunotherapy Cyclophosphamide Dendritic cell vaccine Neoantigen Neoepitope Ovarian cancer